<DOC>
	<DOCNO>NCT01706523</DOCNO>
	<brief_summary>This open-label extension protocol provide necessary data safety , tolerability , pharmacokinetics efficacy STX209 among subject ASD .</brief_summary>
	<brief_title>Open Label Extension Study STX209 ( Arbaclofen ) Autism Spectrum Disorders</brief_title>
	<detailed_description>This open label extension study enrol invitation subject complete Seaside protocols 209AS208 22007 . Protocol 209AS208 , `` A Randomized , Double-Blind , Placebo-Controlled , Study Efficacy , Safety , Tolerability STX209 ( Arbaclofen ) Administered Treatment Social Withdrawal Subjects Autism Spectrum Disorders . '' Protocol 22007 , `` An Open Label Extension Study Evaluate Safety , Tolerability Pharmacokinetics STX209 Subjects Autism Spectrum Disorder . '' This open-label extension provide data follow : 1 . Evaluate safety tolerability long term use STX209 ( Arbaclofen ) 2 . Provide support pharmacokinetic analysis 3 . Assess long term efficacy social behavior subject ASD .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Autistic Disorder</mesh_term>
	<mesh_term>Autism Spectrum Disorder</mesh_term>
	<mesh_term>Child Development Disorders , Pervasive</mesh_term>
	<criteria>Subject complete study 22007 209AS208 , show adequately follow protocol , adequate medical justification enter study . Parent legallyauthorized representative caregiver willing able perform protocolspecified function . Treatment 2 psychoactive medication Subjects history seizure disorder must adequately wellcontrolled , specify study protocol For female subject , negative pregnancy test Comorbid condition might interfere conduct study confound interpretation study data , endanger subject . Current use illicit drug alcohol abuse . Subjects serious adverse event adverse event study 22007 209AS208 related STX209 , endangers subject , opinion investigator Current use another investigational drug , vigabatrin , tiagabine , riluzole</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>Autism Spectrum Disorders</keyword>
	<keyword>Autism</keyword>
	<keyword>Asperger</keyword>
	<keyword>Pervasive Developmental Disorder - Not otherwise specify</keyword>
</DOC>